Notably, the addition of veliparib to cisplatin had a positive impact on PFS in patients with BRCA-like metastatic TNBC, while no such effect was observed in individuals with non-BRCA metastatic breast cancer; however, it is important to note that these differences did not reach statistical significance. 83 PARP Inhibitors + New Hormonal Agent (NHA) The combination of PARP inhibitors and NAH has ushered in a new era as a first-line treatment option. 84 , 85 Notable published studies on the use of a PARPi plus NHA as a first-line treatment for mCRPC include PROpel, 86 TALAPRO-2, 87 and
1
—
—